Page last updated: 2024-08-21

alpha-aminopyridine and Acute Myelogenous Leukemia

alpha-aminopyridine has been researched along with Acute Myelogenous Leukemia in 90 studies

Research

Studies (90)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (2.22)	29.6817
2010's	43 (47.78)	24.3611
2020's	45 (50.00)	2.80

Authors

Authors	Studies
Carayannopoulos, L; Cheng, Y; Li, Y; Reyes, J; Tong, Z; Wang, X; Zhou, S	1
Bennett, JM; de Botton, S; DiNardo, CD; Döhner, H; Fathi, AT; Frattini, MG; Gong, J; Hasan, M; Kantarjian, HM; Lersch, F; Martin-Regueira, P; Montesinos, P; Schuh, AC; Stein, EM; Vyas, P; Wei, AH; Zeidan, AM	1
Cathelin, S; Chan, SM; Cojocari, D; Leverson, JD; Liu, G; MacBeth, KJ; Narayanaswamy, R; Nicolay, B; Phillips, DC; Ronseaux, S; Sharon, D; Subedi, A	1
Li, J; Li, Y; Liao, D; Niu, T; Wang, F; Wang, Z; Xiong, Y	1
Thol, F	1
Bhalla, KN; Birdwell, CE; Boettcher, S; Daver, N; Davis, JA; DiNardo, CD; Ebert, BL; Fiskus, W; Jin, Q; Kadia, TM; Khoury, JD; McGeehan, GM; Mill, CP; Qi, Y; Sasaki, K; Su, X; Takahashi, K	1
Fu, JH; Li, JL; Li, Z; Qiu, HY; Qiu, QC; Xue, SL; Zhang, J; Zhou, M	1
Almon, C; Chen, Y; Cooper, M; Fan, B; Hossain, M; Hua, L; Nabhan, S; Yang, H; Yin, F	1
Bai, J; Pei, Z; Song, Q; Wang, H; Wang, J; Wu, H; Zhang, B	1
Al Jammal, M; Al-Juhaishi, T; Al-Kindi, SG; Arora, S; Badhwar, A; Chahine, N; Chami, T; Hajjari, J; Heisler, AC; Hoit, BD; Janus, SE; Mously, H	1
Deng, M; Liu, S; Peng, H; Xiao, H; Xiao, X; Yuan, H	1
Copher, R; Gajra, A; Hou, Y; Klink, AJ; Knoth, RL; Marshall, L; McBride, A	1
Guo, H; Jin, R; Nie, F; Tang, T; Tang, Y; Wang, Y; Zhou, S	1
Brattås, MK; Hatfield, KJ; Hemsing, AL; Reikvam, H; Rye, KP	1
Stein, EM	2
Chen, C; Jiang, ZX; Li, ZX; Liu, Y; Liu, YF; Liu, YJ; Wang, C; Wang, SJ; Yan, MM; Yang, L; Zhang, DF; Zhang, W; Zhang, Y; Zhou, DB	1
Long, ZJ; Wang, JD; Weng, JY; Xu, JQ	1
Cai, H; Cheng, J; Dai, Z; Ge, T; Hu, G; Huang, L; Jin, J; Mao, X; Mu, W; Wang, J; Yang, Y; Zeng, Y; Zhou, J; Zhu, L; Zhu, X	1
Barbat, SH; Cornely, OA; Hodges, MR; Koehler, P; Kramer, WG; Limburg, E; Ostermann, H; Tawadrous, M; Teschner, D	1
Adhikary, R; Ali, MA; Khandelwal, R; Nayarisseri, A; Pancholi, R; Singh, SK; Srinitha, S; Sweta, J; Vuree, S	1
Huang, YQ; Ma, XD; Wu, RJ; Zheng, RJ	1
Chen, Q; Dai, Y; Fang, Z; Li, Y; Lin, F; Shi, Y; Xu, B; Ye, J; Yu, Y; Yuan, D; Zha, J	1
Dittakavi, S; Hallur, G; Kiran, V; Mullangi, R; Purra, BR; Zakkula, A	1
DiNardo, CD; Wei, AH	1
Bashash, D; Esmaeili, S; Pourbagheri-Sigaroodi, A; Sadeghi, S; Safaroghli-Azar, A	1
Bollag, G; Frankfurt, O; Hsu, HH; Kayser, S; Lam, B; Le, MH; Levis, MJ; Pagel, JM; Perl, AE; Roboz, GJ; Severson, PL; Smith, CC; Stone, RM; Wang, ES; West, BL; Zhang, C	1
Beaver, JA; Charlab, R; de Claro, RA; Deisseroth, A; Dorff, SE; Farrell, AT; Kazandjian, D; Mulkey, F; Norsworthy, KJ; Pazdur, R; Przepiorka, D; Scott, EC; Sridhara, R; Ward, AF	1
Dong, A; Guo, W; He, Z; Huang, H; Yang, W; Yao, R; Zhou, X	1
Zeidner, JF	1
Naoe, T	1
Duong, VH; Kallen, ME; Koka, R; Sanchez-Petitto, G; Singh, Z; Yared, JA; Zaman, QU	1
Xia, X	1
Arber, DA; Erba, HP	1
Chen, G; Fang, M; Gao, S; Gao, X; Li, X; Li, Y; Liu, H; Liu, Z; Luo, J; Ma, Y; Shen, J; Sun, K; Wang, L; Wang, X; Wei, X; Yang, L; Yu, L; Zhang, Y; Zhou, W	1
Bae, SH; Cheong, JW; Jeung, HK; Kim, Y; Lee, JI; Min, YH; Song, J	1
Bi, S; Chen, K; Chen, XL; Dai, Y; Deng, M; Feng, L; Fu, G; Xu, B; Xu-Monette, ZY; Yang, Q; Young, KH; Zha, J; Zhou, Y	1
Cardinali, V; Cerchione, C; Falini, B; Martelli, MP; Martinelli, G; Martino, G	1
Moore, DC; Muslimani, A; Nelson, V	1
Almon, C; Choe, S; Cooper, M; DiNardo, CD; Döhner, H; Fan, B; Fathi, AT; Franovic, A; Frattini, MG; Hua, L; Kantarjian, HM; Lersch, F; Löwenberg, B; McCloskey, JK; Mims, AS; Nabhan, S; Odenike, O; Ossenkoppele, GJ; Patel, PA; Pollyea, DA; Pratz, KW; Roshal, M; Savona, MR; Seet, CS; Stein, AS; Stein, EM; Stone, RM; Tallman, MS; Wang, H; Winer, ES; Wu, B	1
Chen, L; Chen, M; Cheng, P; Dou, C; Huang, Q; Liu, H; Liu, L; Liu, X; Ren, S; Wang, C; Wei, P; Zhang, H; Zhang, J; Zhang, X	1
Chen, XS; Dou, LP; Gao, CJ; Li, YH; Liu, DH; Liu, SJ; Liu, YC; Pang, BX; Wang, H; Wang, MZ; Wang, XK; Yan, F; Zhu, CY	1
Carter, BZ; Chen, F; Cheng, J; Fang, D; Jiang, L; Jiang, X; Meng, F; Ni, J; Wang, Q; Wang, Z; Yi, Z; Yin, C; Yu, G; Zhong, Q	1
Avanzino, B; Chopra, VS; DiMartino, JF; Figueroa, ME; MacBeth, KJ; Quek, L; Schwickart, M; See, WL; Tang, L; Zheng, B	1
Andrew Futreal, P; Bhalla, KN; DiNardo, CD; Frattini, M; Furudate, K; Garcia-Manero, G; Gumbs, C; Jabbour, E; Kadia, TM; Kantarjian, HM; Konopleva, M; Little, LD; Liu, G; MacBeth, KJ; Matthews, JA; Morita, K; Patel, KP; Ravandi, F; Song, X; Takahashi, K; Tanaka, T; Thompson, EJ; Wang, F; Wu, B; Yan, Y; Zhang, J	1
Bal, N; Bergl, PA; Bursch, K; Carlson, KS; Hernandez, JR; Khan, M; Roddy, JT	1
Graff, JP; Karnati, T; Lee, D; Omofoye, OA; Shahlaie, K	1
Buhlinger, K; Coombs, CC; Foster, MC; Galeotti, J; Kaiser-Rogers, K; Montgomery, ND; Nichols, A; Ramkissoon, LA; Richardson, DR; Zeidner, JF	1
Boissel, N; Brandwein, JM; Cameron, C; Chantepie, S; de Botton, S; Frattini, MG; Hunault-Berger, M; Hutton, B; Legrand, O; Marion-Gallois, R; Milkovich, G; Nehme, SA; Pigneux, A; Quesnel, B; Recher, C; Siddiqui, M; Stein, EM; Thomas, X; Tosolini, A; Wang, JJ; Wei, AH	1
Majeti, R; Thomas, D	1
DiNardo, CD; Medeiros, BC; Stone, RM	1
Lun, Y; Wu, Y; Yang, JJ	1
Sheridan, C	1
Chen, K; Deng, M; Deng, S; Li, J; Li, P; Li, Y; Wang, Y; Xu, B; Zhang, L; Zhou, Y	1
Kim, ES	1
Garber, K	1
Tiong, IS; Wei, AH	2
Haroun, F; Lap, CJ; Nassereddine, S; Tabbara, I	1
Stone, RM; Yogarajah, M	1
Patel, SA	1
Attar, EC; de Botton, S; DiNardo, CD; Fathi, AT; Gupta, I; Kenvin, L; Kline, I; Stein, EM	1
DiNardo, C	1
Dugan, J; Pollyea, D	1
Roboz, GJ	1
Agresta, S; Alsafadi, S; Amatangelo, M; Bernard, OA; David, MD; De Botton, S; Heiblig, M; Kennedy, A; Levine, R; MacBeth, K; Metzner, M; Penard-Lacronique, V; Peniket, A; Quek, L; Quivoron, C; Saada, V; Shih, A; Stein, E; Stoilova, B; Thakurta, A; Vassiliou, GS; Vijayabaskar, MS; Vyas, P; Willekens, C; Yen, K	1
Killock, D	1
Sweet, K; Talati, C	1
Coombs, CC; Galeotti, J	1
Bansal, P; Bhatia, R; Dogra, R; Rawal, RK; Shankar, R	1
Anand, K; Iyer, SP; Kumar, P; Pati, D; Pingali, SR	1
Bullinger, L	1
Agresta, SV; Attar, EC; Collins, R; de Botton, S; DiNardo, CD; Frattini, MG; Kantarjian, HM; MacBeth, KJ; Pollyea, DA; See, WL; Stein, AS; Stein, EM; Tallman, MS; Tosolini, A; Xu, Q	1
DiNardo, C; Guerra, VA; Konopleva, M	1
Estey, EH; Percival, MM	1
Gao, X; Jiang, M; Ning, Q; Wang, J; Wang, L; Yao, Y; Yu, L; Zhou, J	1
Galanis, A; Levis, M	1
Bashir, A; Bollag, G; Burton, EA; Carias, H; Damon, LE; Habets, G; Hsu, HH; Ibrahim, PN; Kasarskis, A; Lasater, EA; Le, MH; Lin, KC; Massi, E; Matusow, B; Pendleton, M; Perl, A; Powell, B; Sebra, R; Shah, NP; Shellooe, R; Smith, CC; Spevak, W; Tsang, G; West, BL; Zhang, C; Zhang, J; Zhang, Y	1
Chen, K; Deng, M; Jiang, Z; Li, J; Li, P; Li, Y; Liang, J; Wang, W; Wang, X; Wei, X; Xiao, Y; Xu, B; Yao, Y; Ye, W; Zheng, Z; Zhou, Y	1
Kiyoi, H	1
Allegretti, M; Amadori, S; Bertolini, F; Foà, R; Licchetta, R; Mirabilii, S; Orecchioni, S; Reggiani, F; Ricciardi, MR; Tafuri, A; Talarico, G; Torrisi, MR	1
Andreeff, M; Borthakur, G; Burger, J; Cortes, J; Daver, N; DeBose, L; DiNardo, CD; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Konopleva, M; Kornblau, S; Pemmaraju, N; Ragon, BK; Ravandi, F; Schneider, H; Wierda, W; Zeng, Z	1
Artin, E; Bawa, O; Bernard, OA; Biller, SA; Broutin, S; Chen, Y; Choe, S; Cianchetta, G; Dang, L; David, MD; de Botton, S; DeLaBarre, B; Dorsch, M; Fang, C; Gross, S; Jiang, F; Jin, L; Jin, S; Konteatis, Z; Liu, W; Marteyn, BS; Nagaraja, R; Opolon, P; Paci, A; Padyana, A; Penard-Lacronique, V; Pilichowska, M; Quivoron, C; Saada, V; Salituro, FG; Saunders, JO; Silverman, L; Straley, K; Su, SM; Tobin, E; Travins, J; Wang, F; Wei, W; Xu, Y; Yang, H; Yen, K	1
Garrett-Bakelman, FE; Glass, J; Gliser, C; Intlekofer, AM; Knapp, K; Levine, RL; Mason, CE; Melnick, A; Meydan, C; Nazir, A; Shank, K; Shih, AH; Stein, EM; Straley, K; Thompson, CB; Travins, J; Ward, PS; Yen, K	1
Cole, R; Gregory, GP; Johnstone, RW; Kats, LM; Li, J; Nagaraja, R; Rogers, AJ; Vervoort, SJ; Vidacs, E; Yen, KE	1
Downing, JR	1
Berchuck, JE; Carr, SA; Carroll, M; Clauser, K; Davis, TN; DeAngelo, DJ; Galinsky, I; Golub, TR; Hahn, CK; Hahn, WC; Kakoza, RM; Kung, AL; Root, DE; Ross, KN; Ross, L; Schinzel, AC; Silver, SJ; Stegmaier, K; Stone, RM	1
Furihata, M; Ikezoe, T; Isaka, M; Koeffler, HP; Kojima, S; Nishioka, C; Takeuchi, A; Yang, J; Yokoyama, A	1

Reviews

17 review(s) available for alpha-aminopyridine and Acute Myelogenous Leukemia

Article	Year
Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database. Current problems in cardiology, 2022, Volume: 47, Issue:11 Topics: Adolescent; Adult; Aminopyridines; Anthracyclines; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Decitabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pericarditis; Pharmacovigilance; Sulfonamides; Triazines; United States; United States Food and Drug Administration	2022
[Chidamide combined with chemotherapy for treatment of therapy-related acute myeloid leukemia secondary to peripheral T-cell lymphoma: a case report and literatures review]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2019, 08-14, Volume: 40, Issue:8 Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Peripheral	2019
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement. Nagoya journal of medical science, 2020, Volume: 82, Issue:2 Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines	2020
Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). American journal of clinical pathology, 2020, 11-04, Volume: 154, Issue:6 Topics: Aged; Aminopyridines; Antineoplastic Agents; Blood Cells; Bone Marrow; Bone Marrow Examination; Chromosome Aberrations; Cytarabine; Cytogenetic Analysis; Daunorubicin; DNA Mutational Analysis; Genetic Predisposition to Disease; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; PubMed; Triazines	2020
Enasidenib and ivosidenib in AML. Minerva medica, 2020, Volume: 111, Issue:5 Topics: Aminopyridines; Antineoplastic Agents; Cell Differentiation; Clinical Trials as Topic; Glutarates; Glycine; Humans; Isocitrate Dehydrogenase; Isocitrates; Ketoglutaric Acids; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Mutation, Missense; NADP; Pyridines; Syndrome; Triazines	2020
Novel Therapeutics in Acute Myeloid Leukemia. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2017, Volume: 37 Topics: Aminopyridines; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Triazines	2017
Enasidenib: First Global Approval. Drugs, 2017, Volume: 77, Issue:15 Topics: Administration, Oral; Aminopyridines; Drug Approval; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Triazines; United States; United States Food and Drug Administration	2017
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood, 2017, 12-07, Volume: 130, Issue:23 Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Liposomes; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins c-bcl-2; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Treatment Outcome; Triazines	2017
The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia. Annals of hematology, 2017, Volume: 96, Issue:12 Topics: Aminopyridines; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Proto-Oncogene Proteins c-bcl-2; Triazines	2017
A concise review of BCL-2 inhibition in acute myeloid leukemia. Expert review of hematology, 2018, Volume: 11, Issue:2 Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2; Staurosporine; Triazines	2018
Enasidenib for the treatment of acute myeloid leukemia. Expert review of clinical pharmacology, 2018, Volume: 11, Issue:8 Topics: Adult; Aminopyridines; Antineoplastic Agents; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Triazines	2018
Recently approved therapies in acute myeloid leukemia: A complex treatment landscape. Leukemia research, 2018, Volume: 73 Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Cytarabine; Daunorubicin; Female; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Pyridines; Staurosporine; Triazines	2018
Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia. Anti-cancer agents in medicinal chemistry, 2018, Volume: 18, Issue:14 Topics: Aminopyridines; Antineoplastic Agents; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Recurrence; Triazines	2018
New drugs creating new challenges in acute myeloid leukemia. Genes, chromosomes & cancer, 2019, Volume: 58, Issue:12 Topics: Aminopyridines; Aniline Compounds; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyridines; Staurosporine; Triazines; United States; United States Food and Drug Administration	2019
Venetoclax-based therapies for acute myeloid leukemia. Best practice & research. Clinical haematology, 2019, Volume: 32, Issue:2 Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sulfonamides; Triazines	2019
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia. Cancer, 2019, Sep-15, Volume: 125, Issue:18 Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles	2019
Overview: A New Era of Cancer Genome in Myeloid Malignancies. Oncology, 2015, Volume: 89 Suppl 1 Topics: Aminopyridines; Anemia, Aplastic; Antineoplastic Agents; Benzimidazoles; Clonal Evolution; Genome, Human; Hematopoiesis; Histone-Lysine N-Methyltransferase; Humans; Immunosuppressive Agents; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Methyltransferases; Molecular Targeted Therapy; Mutation; Myelodysplastic Syndromes; Triazines	2015

Trials

11 trial(s) available for alpha-aminopyridine and Acute Myelogenous Leukemia

Article	Year
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. The Lancet. Oncology, 2021, Volume: 22, Issue:11 Topics: Aged; Aminopyridines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Mutation; Progression-Free Survival; Random Allocation; Treatment Outcome; Triazines	2021
Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia. Clinical pharmacology in drug development, 2022, Volume: 11, Issue:4 Topics: Adult; Aminopyridines; Antineoplastic Agents; Consolidation Chemotherapy; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridines; Triazines	2022
Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia. The Journal of antimicrobial chemotherapy, 2023, 11-06, Volume: 78, Issue:11 Topics: Adult; Aminopyridines; Antifungal Agents; Humans; Leukemia, Myeloid, Acute; Neutropenia	2023
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. Blood advances, 2020, 04-28, Volume: 4, Issue:8 Topics: Aminopyridines; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles	2020
Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study. Clinical epigenetics, 2020, 09-01, Volume: 12, Issue:1 Topics: Aclarubicin; Adolescent; Adult; Aminopyridines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Decitabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Treatment Outcome; Young Adult	2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood, 2021, 04-01, Volume: 137, Issue:13 Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Female; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pyridines; Treatment Outcome; Triazines; Young Adult	2021
Positive First Trial of Enasidenib for AML. Cancer discovery, 2017, Volume: 7, Issue:8 Topics: Adult; Aged; Aminopyridines; Disease-Free Survival; Female; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Triazines	2017
Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia. Future oncology (London, England), 2018, Volume: 14, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Bone Marrow Cells; Cell Differentiation; Disease-Free Survival; Female; GTP Phosphohydrolases; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Membrane Proteins; Middle Aged; Mutant Proteins; Mutation; Recurrence; Triazines	2018
Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study. JAMA oncology, 2018, 08-01, Volume: 4, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Syndrome; Triazines	2018
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia, 2019, Volume: 33, Issue:11 Topics: Aged; Aged, 80 and over; Aminopyridines; Enzyme Inhibitors; Female; Hematologic Diseases; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mutant Proteins; Mutation; Remission Induction; Treatment Outcome; Triazines	2019
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. American journal of hematology, 2017, Volume: 92, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2017

Other Studies

62 other study(ies) available for alpha-aminopyridine and Acute Myelogenous Leukemia

Article	Year
Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. Journal of clinical pharmacology, 2022, Volume: 62, Issue:4 Topics: Aged; Aminopyridines; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Digoxin; Drug Interactions; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Membrane Transport Proteins; Myelodysplastic Syndromes; Neoplasm Proteins; Pharmaceutical Preparations; Recurrence; Rosuvastatin Calcium; Triazines	2022
Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia. Leukemia, 2022, Volume: 36, Issue:3 Topics: Aminopyridines; Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Sulfonamides; Triazines	2022
RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both Leukemia & lymphoma, 2022, Volume: 63, Issue:5 Topics: Aminopyridines; Apoptosis; Benzamides; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Receptor-Interacting Protein Serine-Threonine Kinases	2022
What to use to treat AML: the role of emerging therapies. Hematology. American Society of Hematology. Education Program, 2021, 12-10, Volume: 2021, Issue:1 Topics: Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Approval; Drug Discovery; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Triazines	2021
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood cancer journal, 2022, 01-11, Volume: 12, Issue:1 Topics: Aminopyridines; Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Gene Expression Regulation, Leukemic; Gene Rearrangement; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; Mutation; Myeloid-Lymphoid Leukemia Protein; Nucleophosmin; Proto-Oncogene Proteins; Sulfonamides	2022
Epigenetic therapy with chidamide alone or combined with 5‑azacitidine exerts antitumour effects on acute myeloid leukaemia cells Oncology reports, 2022, Volume: 47, Issue:4 Topics: Aminopyridines; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzamides; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Synergism; Epigenomics; Humans; Leukemia, Myeloid, Acute; U937 Cells; Up-Regulation	2022
Chidamide and Decitabine in Combination with a HAG Priming Regimen for Acute Myeloid Leukemia with TP53 Mutation. Acta medica Okayama, 2022, Volume: 76, Issue:1 Topics: Adult; Aged; Aminopyridines; Antimetabolites, Antineoplastic; Benzamides; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Remission Induction; Retrospective Studies; Treatment Outcome; Tumor Suppressor Protein p53	2022
Chidamide works synergistically with Dasatinib by inducing cell-cycle arrest and apoptosis in acute myeloid leukemia cells. Molecular and cellular biochemistry, 2023, Volume: 478, Issue:4 Topics: Aminopyridines; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dasatinib; Humans; Leukemia, Myeloid, Acute	2023
Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia. Leukemia research, 2022, Volume: 122 Topics: Aminopyridines; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Triazines	2022
Design, synthesis, AML activity and molecular modeling of novel IDH2 inhibitors. Bioorganic chemistry, 2023, Volume: 130 Topics: Aminopyridines; Animals; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Rats; Triazines	2023
Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition. International journal of molecular sciences, 2022, Nov-25, Volume: 23, Issue:23 Topics: Aminopyridines; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Signal Transduction; Syk Kinase	2022
IDH2 inhibition in AML. Blood, 2023, 01-12, Volume: 141, Issue:2 Topics: Aged; Aminopyridines; Humans; Leukemia, Myeloid, Acute; Triazines	2023
Zhongguo shi yan xue ye xue za zhi, 2023, Volume: 31, Issue:1 Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Adult; Aminopyridines; Apoptosis; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Humans; Jurkat Cells; Leukemia, Myeloid, Acute; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Proportional Hazards Models; Risk Factors; RNA, Messenger; Survival Analysis; Tumor Microenvironment	2023
Disruption of mitochondrial oxidative phosphorylation by chidamide eradicates leukemic cells in AML. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023, Volume: 25, Issue:6 Topics: Aminopyridines; Animals; Apoptosis; Benzamides; Cell Line, Tumor; Leukemia, Myeloid, Acute; Mice; Oxidative Phosphorylation	2023
Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia. Cancer immunology, immunotherapy : CII, 2023, Volume: 72, Issue:7 Topics: Aminopyridines; Decitabine; Humans; Immunotherapy, Adoptive; Leukemia, Myeloid, Acute; T-Lymphocytes	2023
Identification of High-Affinity Small Molecule Targeting IDH2 for the Clinical Treatment of Acute Myeloid Leukemia. Asian Pacific journal of cancer prevention : APJCP, 2019, 08-01, Volume: 20, Issue:8 Topics: Aminopyridines; High-Throughput Screening Assays; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Models, Molecular; Molecular Docking Simulation; Small Molecule Libraries; Triazines	2019
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair. Clinical epigenetics, 2019, 10-07, Volume: 11, Issue:1 Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Repair; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Leukemia, Myeloid, Acute; Membrane Potential, Mitochondrial; Mice; Myeloid-Lymphoid Leukemia Protein; Oncogene Proteins, Fusion; Proto-Oncogene Proteins; Small Molecule Libraries; Xenograft Model Antitumor Assays	2019
Validated LC-MS/MS Method for Simultaneous Quantitation of Enasidenib and its Active Metabolite, AGI-16903 in Small Volume Mice Plasma: Application to a Pharmacokinetic Study. Drug research, 2020, Volume: 70, Issue:1 Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Humans; Leukemia, Myeloid, Acute; Male; Mice; Models, Animal; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Triazines	2020
How I treat acute myeloid leukemia in the era of new drugs. Blood, 2020, 01-09, Volume: 135, Issue:2 Topics: Adult; Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Mutation; Prognosis; Pyrazines; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Triazines	2020
PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest Turkish journal of haematology : official journal of Turkish Society of Haematology, 2020, 08-28, Volume: 37, Issue:3 Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; Humans; Leukemia, Myeloid, Acute; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured; U937 Cells	2020
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 08-15, Volume: 26, Issue:16 Topics: Aminopyridines; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridines; Triazines; United States; United States Food and Drug Administration	2020
Bioinformatics analysis of the network of histone H3 lysine 9 trimethylation in acute myeloid leukaemia. Oncology reports, 2020, Volume: 44, Issue:2 Topics: Aminopyridines; Apoptosis; Benzamides; Chromatin Immunoprecipitation Sequencing; Computational Biology; Drug Resistance, Neoplasm; Gene Regulatory Networks; Histone Deacetylase Inhibitors; Histones; Humans; Leukemia, Myeloid, Acute; Protein Interaction Maps; THP-1 Cells	2020
Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 08-15, Volume: 26, Issue:16 Topics: Aminopyridines; Cell Differentiation; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridines; Triazines; United States; United States Food and Drug Administration	2020
Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy. Leukemia research, 2020, Volume: 96 Topics: Aminopyridines; Cellulitis; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neutrophils; Prognosis; Skin Diseases; Triazines	2020
Drug efficacy and toxicity prediction: an innovative application of transcriptomic data. Cell biology and toxicology, 2020, Volume: 36, Issue:6 Topics: Aminophenols; Aminopyridines; Animals; Antineoplastic Agents; Benzodioxoles; Cell Death; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Combinations; Drug Development; Epithelial Cells; Gene Expression Profiling; Gene Regulatory Networks; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyrazoles; Quinolones; Toxicity Tests; Transcriptome	2020
All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells. Yonsei medical journal, 2020, Volume: 61, Issue:9 Topics: Aminopyridines; Antineoplastic Agents; Cell Differentiation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Tretinoin; Triazines	2020
Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia. Cell death & disease, 2020, 09-18, Volume: 11, Issue:9 Topics: Aminopyridines; Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzamides; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Humans; Leukemia, Myeloid, Acute; Sulfonamides	2020
Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma. Annals of hematology, 2021, Volume: 100, Issue:12 Topics: Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Multiple Myeloma; Triazines	2021
HMGB1: an important regulator of myeloid differentiation and acute myeloid leukemia as well as a promising therapeutic target. Journal of molecular medicine (Berlin, Germany), 2021, Volume: 99, Issue:1 Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Benzamides; Cell Differentiation; Cell Proliferation; Cells, Cultured; Down-Regulation; HMGB1 Protein; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear	2021
Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway. Journal of experimental & clinical cancer research : CR, 2020, Dec-09, Volume: 39, Issue:1 Topics: Adolescent; Adult; Aged; Aminopyridines; Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Child; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proto-Oncogene Proteins c-akt; Salvage Therapy; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Young Adult	2020
Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia. Journal of translational medicine, 2021, 03-21, Volume: 19, Issue:1 Topics: Aminopyridines; Animals; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Enhancer of Zeste Homolog 2 Protein; Humans; Leukemia, Myeloid, Acute; Mice; Smoothened Receptor	2021
Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA. Experimental hematology, 2021, Volume: 98 Topics: Aminopyridines; Azacitidine; Cell Line, Tumor; DNA Methylation; DNA, Neoplasm; Humans; Leukemia, Myeloid, Acute; Triazines	2021
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nature communications, 2021, 05-10, Volume: 12, Issue:1 Topics: Aged; Aminopyridines; Antineoplastic Agents; CCAAT-Enhancer-Binding Proteins; Core Binding Factor Alpha 2 Subunit; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epigenomics; Evolution, Molecular; Female; Glycine; High-Throughput Nucleotide Sequencing; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Multigene Family; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Pyridines; ras Proteins; Repressor Proteins; RNA-Seq; Signal Transduction; Single-Cell Analysis; Stem Cells; Triazines	2021
Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH-inhibitor therapy for AML. British journal of haematology, 2021, Volume: 194, Issue:6 Topics: Aged; Aminopyridines; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Ketosis; Leukemia, Myeloid, Acute; Male; Triazines	2021
Intracranial myeloid sarcoma presentation in distant acute myeloid leukemia remission. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2021, Volume: 89 Topics: Adult; Aminopyridines; Brain Neoplasms; Cytarabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Remission Induction; Sarcoma, Myeloid; Triazines	2021
Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after enasidenib treatment. Leukemia & lymphoma, 2021, Volume: 62, Issue:12 Topics: Aminopyridines; Clonal Evolution; Humans; Leukemia, Myeloid, Acute; Philadelphia Chromosome; Triazines	2021
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis. Cancer medicine, 2021, Volume: 10, Issue:18 Topics: Adolescent; Adult; Aged; Aminopyridines; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Female; France; Humans; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Multicenter Studies as Topic; Mutation; Neoplasm Recurrence, Local; Observational Studies as Topic; Propensity Score; Standard of Care; Treatment Outcome; Triazines; Young Adult	2021
Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models. Cancer discovery, 2017, Volume: 7, Issue:5 Topics: Aminopyridines; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Triazines	2017
Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy. Journal of clinical pharmacy and therapeutics, 2017, Volume: 42, Issue:6 Topics: Adult; Aminopyridines; Antineoplastic Agents; Benzamides; Female; Humans; Leukemia, Myeloid, Acute; Myeloid-Lymphoid Leukemia Protein; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Pyridines; Remission Induction	2017
First new drug approval for AML in 15 years. Nature biotechnology, 2017, 08-08, Volume: 35, Issue:8 Topics: Aminoglycosides; Aminopyridines; Aniline Compounds; Antibodies, Monoclonal, Humanized; Drug Approval; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Staurosporine; Triazines	2017
Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells. Clinical epigenetics, 2017, Volume: 9 Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; DNA Damage; DNA Repair; Drug Therapy; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplastic Stem Cells; Young Adult	2017
First metabolic oncology inhibitor gets FDA green light, with record price tag. Nature biotechnology, 2017, 10-11, Volume: 35, Issue:10 Topics: Aminopyridines; Drug Approval; Drug Industry; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Triazines; United States; United States Food and Drug Administration	2017
Enasidenib-Induced Differentiation Syndrome in IDH2-Mutant Acute Myeloid Leukemia. JAMA oncology, 2018, 08-01, Volume: 4, Issue:8 Topics: Aminopyridines; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Triazines	2018
In brief: Two new drugs for AML. The Medical letter on drugs and therapeutics, 2018, 03-26, Volume: 60, Issue:1543 Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Liposomes; Mutation; Treatment Outcome; Triazines	2018
Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation. Clinical advances in hematology & oncology : H&O, 2018, Volume: 16, Issue:4 Topics: Aminopyridines; Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Multicenter Studies as Topic; Mutation; Prognosis; Recurrence; Research; Treatment Outcome; Triazines	2018
Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience. Clinical advances in hematology & oncology : H&O, 2018, Volume: 16, Issue:5 Topics: Administration, Oral; Aminopyridines; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Gene Expression Regulation, Neoplastic; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Prognosis; Recurrence; Remission Induction; Survival Analysis; Triazines	2018
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nature medicine, 2018, Volume: 24, Issue:8 Topics: Aminopyridines; Cell Differentiation; Clone Cells; Cohort Studies; Hematopoiesis; Humans; Immunophenotyping; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Triazines	2018
Uncovering the clonal basis of response and resistance to IDH2 inhibition in AML. Nature reviews. Clinical oncology, 2018, Volume: 15, Issue:10 Topics: Aminopyridines; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Triazines	2018
Enasidenib-induced eosinophilic differentiation in a patient with acute myeloid leukaemia with IDH2 and U2AF1 mutations. British journal of haematology, 2019, Volume: 184, Issue:4 Topics: Aged; Aminopyridines; Cell Differentiation; Eosinophils; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Mutation; Splicing Factor U2AF; Triazines	2019
Acute myeloid leukemia with eosinophilia after cyclin-dependent kinases 4/6 inhibitor treatment due to underlying clonal hematopoiesis of indeterminate potential. American journal of hematology, 2019, Volume: 94, Issue:3 Topics: Adult; Aminopyridines; Animals; Antigens, Nuclear; Antineoplastic Agents; Cell Cycle Proteins; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Models, Animal; DNA-Binding Proteins; Eosinophilia; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Nuclear Proteins; Phosphoproteins; Protein Kinase Inhibitors; Purines	2019
IDH2 inhibition: another piece to the puzzle. Blood, 2019, 02-14, Volume: 133, Issue:7 Topics: Aminopyridines; Humans; Leukemia, Myeloid, Acute; Triazines	2019
Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine. PloS one, 2013, Volume: 8, Issue:8 Topics: Aminopyridines; Antigens, Neoplasm; Apoptosis; Azacitidine; Benzamides; Blotting, Western; Cell Cycle; Cell Line, Tumor; Decitabine; Flow Cytometry; Histone Deacetylase Inhibitors; HLA-A Antigens; Humans; Leukemia, Myeloid, Acute; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes, Cytotoxic	2013
Inhibition of c-Kit by tyrosine kinase inhibitors. Haematologica, 2015, Volume: 100, Issue:3 Topics: Aminopyridines; Antineoplastic Agents; Benzothiazoles; Biomarkers; Bone Marrow; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; fms-Like Tyrosine Kinase 3; Gene Expression; Hair; Hematopoietic Stem Cells; Humans; Indazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pigmentation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Thiazoles	2015
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. Cancer discovery, 2015, Volume: 5, Issue:6 Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzothiazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; fms-Like Tyrosine Kinase 3; Heterografts; Humans; Leukemia, Myeloid, Acute; Mice; Models, Molecular; Molecular Conformation; Mutation; Phenylurea Compounds; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Pyrroles; Recurrence; Structure-Activity Relationship	2015
A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor. Current cancer drug targets, 2015, Volume: 15, Issue:6 Topics: Adult; Aminopyridines; Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; CD40 Antigens; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid, Acute; Male; Membrane Potential, Mitochondrial; Middle Aged; Molecular Targeted Therapy; Neoplastic Stem Cells; NF-kappa B; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Time Factors; Tumor Cells, Cultured; Young Adult	2015
The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. Scientific reports, 2015, Dec-17, Volume: 5 Topics: Adult; Aged; Aminopyridines; Animals; Blotting, Western; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Middle Aged; Morpholines; Proto-Oncogene Proteins c-akt; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; U937 Cells; Xenograft Model Antitumor Assays	2015
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic Cancer discovery, 2017, Volume: 7, Issue:5 Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mice; Mutation; Triazines; Xenograft Model Antitumor Assays	2017
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in Cancer discovery, 2017, Volume: 7, Issue:5 Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; fms-Like Tyrosine Kinase 3; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mice; Mice, Mutant Strains; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins; Signal Transduction; Triazines	2017
A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML. Leukemia, 2017, Volume: 31, Issue:6 Topics: Aminopyridines; Antineoplastic Agents; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pharmacogenetics; Triazines	2017
Can treating the SYK cell cure leukemia? Cancer cell, 2009, Oct-06, Volume: 16, Issue:4 Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Regulation, Leukemic; Genomics; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Morpholines; Oxazines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyridines; Pyrimidines; Quinazolines; Syk Kinase; Time Factors; Tyrosine	2009
Proteomic and genetic approaches identify Syk as an AML target. Cancer cell, 2009, Oct-06, Volume: 16, Issue:4 Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genomics; HL-60 Cells; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Morpholines; Oxazines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyridines; Pyrimidines; Quinazolines; RNA Interference; Syk Kinase; Tandem Mass Spectrometry; Time Factors; Tumor Cells, Cultured; Tyrosine; U937 Cells; Xenograft Model Antitumor Assays	2009
Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia. International journal of cancer, 2011, Nov-15, Volume: 129, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antigens, CD34; Bone Marrow; Female; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Male; Middle Aged; Molecular Targeted Therapy; Prognosis; Pyrazoles	2011